Peer-Reviewed Publication

Clin Gastroenterol Hepatol2022;20(11):2514-2523.e3.November 1, 2022Clinical Trial Protocol

Image-Enhanced Endoscopy and Molecular Biomarkers Vs Seattle Protocol to Diagnose Dysplasia in Barrett's Esophagus.

Mathew Vithayathil¹, Ines Modolell², Jacobo Ortiz-Fernandez-Sordo³, Dahmane Oukrif⁴, Apostolos Pappas¹, Wladyslaw Januszewicz⁵, Maria O'Donovan⁶, Andreas Hadjinicolaou⁷, Michele Bianchi¹, Adrienn Blasko¹, Jonathan White³, Philip Kaye⁸, Marco Novelli⁴, Lorenz Wernisch⁹, Krish Ragunath³, Massimiliano di Pietro¹⁰

¹Medical Research Council Cancer Unit, University of Cambridge, United Kingdom.

²Department of Gastroenterology, University Hospital National Health Service Foundation Trust, United Kingdom.

³Nottingham Digestive Diseases Centre, National Institute of Health Research Nottingham Biomedical Research Centre, United Kingdom.

⁴Department of Histopathology, University College London Hospital, Longdon, United Kingdom.

⁵Medical Research Council Cancer Unit, University of Cambridge, United Kingdom; Department of Gastroenterology, Hepatology and Clinical Oncology, Medical Centre for Postgraduate Education, Warsaw, Poland.

⁶Department of Histopathology, Cambridge University Hospital National Health Service Foundation Trust, United Kingdom.

⁷Medical Research Council Cancer Unit, University of Cambridge, United Kingdom; Department of Gastroenterology, University Hospital National Health Service Foundation Trust, United Kingdom.

⁸Department of Histopathology, Nottingham University Hospitals National Health Service Trust, University of Nottingham, United Kingdom.

⁹BIOS Health, Ltd, Cambridge, United Kingdom; Medical Research Council Biostatistics Unit, University of Cambridge, United Kingdom.

¹⁰Medical Research Council Cancer Unit, University of Cambridge, United Kingdom; Department of Gastroenterology, University Hospital National Health Service Foundation Trust, United Kingdom. Electronic address: md460@cam.ac.uk.

PubMed DOI

Abstract

BACKGROUND & AIMS: Dysplasia in Barrett's esophagus often is invisible on high-resolution white-light endoscopy (HRWLE). We compared the diagnostic accuracy for inconspicuous dysplasia of the combination of autofluorescence imaging (AFI)-guided probe-based confocal laser endomicroscopy (pCLE) and molecular biomarkers vs HRWLE with Seattle protocol biopsies. METHODS: Barrett's esophagus patients w…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

BIOS Health
affiliation

Other Funding

Medical Research Council(MR/N501876/1)
United Kingdom
Cancer Research UK
United Kingdom
Department of Health
United Kingdom
Medical Research Council(RG84369)
United Kingdom

MeSH Terms

Humans0Barrett Esophagus*Esophagoscopy0Tumor Suppressor Protein p530Esophageal Neoplasms*Microscopy, Confocal0Biopsy0Hyperplasia0Biomarkers0Aneuploidy0Randomized Controlled Trials as Topic0

Keywords

AutofluorescenceBarrett’s EsophagusConfocal Laser EndomicroscopyDysplasiaEsophageal Adenocarcinoma

Article Info

PMID: 35183768
DOI: 10.1016/j.cgh.2022.01.060
Received: November 15, 2021
Accepted: January 28, 2022

How to Cite

Vithayathil M et al. Image-Enhanced Endoscopy and Molecular Biomarkers Vs Seattle Protocol to Diagnose Dysplasia in Barrett's Esophagus. Clin Gastroenterol Hepatol2022;20(11):2514-2523.e3. doi:10.1016/j.cgh.2022.01.060

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.